Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a director at Werewolf Therapeutics, Inc., reported the sale of 155,885 common shares over three days in early November 2025, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Luke Evnin, a director of Werewolf Therapeutics, Inc. (HOWL), reported the sale of 155,885 shares of common stock across three separate transactions.
• The sales occurred on November 4, 5, and 6, 2025.
• On November 4, 2025, 90,164 shares were sold at a weighted average price of $1.22, with individual transaction prices ranging from $1.17 to $1.30.
• On November 5, 2025, 30,774 shares were sold at a weighted average price of $1.22, with individual transaction prices ranging from $1.19 to $1.25.
• On November 6, 2025, 34,947 shares were sold at a weighted average price of $1.21, with individual transaction prices ranging from $1.185 to $1.27.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• Following these sales, the indirect beneficial ownership of the reporting person, through various MPM entities, stands at 3,787,474 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information. It's a routine part of managing equity holdings for a director.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, undisclosed negative information.

Negatives

• A director's sale of shares, even if pre-planned, reduces insider ownership and can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider trading activity, common in the biotechnology sector where executives and early investors often manage their equity holdings through pre-planned sales.

Related Party Transactions

• Luke Evnin, a director, sold shares indirectly held through entities where he holds management positions (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P.).

Stakeholder Impact

• Shareholders may note a slight reduction in insider ownership, which could be interpreted as a minor negative signal, though the 10b5-1 plan context lessens this impact.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The insider selling by Director Luke Evnin is a routine event, executed under a pre-arranged 10b5-1 plan. This type of transaction typically does not signal a change in the company's fundamental outlook or performance. Investors should view this as a planned liquidity event rather than a bearish signal, and therefore, the filing alone does not warrant a change in investment recommendation.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Biotechnology, Director Transaction